CARsgen Therapeutics (HKG:2171) said it expects to book narrower losses in 2025, according to a Hong Kong bourse filing Monday.
The firm expects a net loss of up to 120 million yuan for the year, compared with the 798 million yuan loss posted a year earlier.
The company's financial results are due in early March.